Therefore, the humanized PD-L1 monoclonal antibodies including Atezolizumab, Avelumab and Durvalumab were approved for treatment of human cancers such as urothelial carcinoma and renal cell carcinoma (120). The gene discussed is CD274; the disease is cancer.